Etzer Darout Analyst Performance

Managing Director & Senior Biotechnology Analyst at BMO Capital Markets

Etzer Darout is a stock analyst at BMO Capital Markets in the healthcare sector, covering 36 publicly traded companies. Over the past year, Etzer Darout has issued 134 stock ratings, including buy, hold, and sell recommendations. While full access to Etzer Darout's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Etzer Darout's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 180 Last 6 Years
Buy Recommendations: 82.49% 146 Buy Ratings
Companies Covered: 36 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	1.7%	3 ratings
Buy	80.8%	143 ratings
Hold	11.9%	21 ratings
Sell	5.6%	10 ratings

Out of 177 total stock ratings issued by Etzer Darout at BMO Capital Markets, the majority (80.8%) have been Buy recommendations, followed by 11.9% Hold, 5.6% Sell, and 1.7% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
MGNX
Sep 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ARVN
Feb 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	36 companies

Etzer Darout, an analyst at BMO Capital Markets, currently covers 36 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Healthcare 36 companies	100.0%

Etzer Darout of BMO Capital Markets specializes in stock coverage within the Healthcare sector.

Coverage Industries

Industry	Percentage
BIOTECHNOLOGY 33 companies	91.7%
PHARMACEUTICALS 3 companies	8.3%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ABVX Abivax	9/22/2026	Reiterated Rating	$103.45	$148.00	Overweight
IOVA Iovance Biotherapeutics	9/17/2026	Boost Price Target	$9.87	$15.00	Overweight
SRRK Scholar Rock	9/15/2026	Downgrade	$51.85		Cautious
SRRK Scholar Rock	9/14/2026	Reiterated Rating	$51.85	$58.00	Equal Weight
SRRK Scholar Rock	9/14/2026	Boost Price Target	$54.13	$84.00	Outperform
XNCR Xencor	9/11/2026	Boost Price Target	$24.26	$35.00	Overweight
MNPR Monopar Therapeutics	9/11/2026	Reiterated Rating	$109.96	$145.00	Overweight
LEGN Legend Biotech	9/11/2026	Lower Price Target	$19.19	$74.00	Overweight
SRRK Scholar Rock	9/10/2026	Boost Price Target	$56.09	$84.00	Outperform
JAZZ Jazz Pharmaceuticals	9/10/2026	Boost Price Target	$241.31	$271.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
PTGX Protagonist Therapeutics	9/1/2026	Boost Price Target	$147.75	$180.00	Overweight
PTGX Protagonist Therapeutics	9/1/2026	Boost Price Target	$147.75	$190.00	Outperform
ELVN Enliven Therapeutics	8/18/2026	Initiated Coverage	$59.53	$78.00	Overweight
PTGX Protagonist Therapeutics	8/17/2026	Boost Price Target	$155.10	$178.00	Outperform
MNPR Monopar Therapeutics	8/13/2026	Reiterated Rating	$114.90	$128.00	Overweight
TRAX First Tracks Biotherapeutics	8/13/2026	Boost Price Target	$46.13	$65.00	Overweight
LEGN Legend Biotech	8/12/2026	Lower Price Target	$21.83	$78.00	Overweight
RLAY Relay Therapeutics	8/7/2026	Boost Price Target	$19.75	$30.00	Overweight
IOVA Iovance Biotherapeutics	8/7/2026	Boost Price Target	$6.17	$13.00	Overweight
CLDX Celldex Therapeutics	8/7/2026	Boost Price Target	$41.56	$53.00	Overweight
PTGX Protagonist Therapeutics	8/6/2026	Boost Price Target	$137.32	$153.00	Overweight
JAZZ Jazz Pharmaceuticals	8/4/2026	Boost Price Target	$251.58	$270.00	Overweight
INCY Incyte	7/29/2026	Boost Price Target	$129.93	$139.00	Overweight
FBRX Forte Biosciences	7/28/2026	Downgrade	$76.50	$77.00	Equal Weight
TRAX First Tracks Biotherapeutics	7/21/2026	Boost Price Target	$36.87	$48.00	Overweight
FBRX Forte Biosciences	7/21/2026	Initiated Coverage	$47.49	$74.00	Overweight
FBRX Forte Biosciences	7/21/2026	Initiated Coverage	$50.73	$74.00	Overweight
PTGX Protagonist Therapeutics	7/14/2026	Boost Price Target	$129.89	$151.00	Overweight
JAZZ Jazz Pharmaceuticals	7/14/2026	Boost Price Target	$236.97	$260.00	Overweight
INCY Incyte	7/14/2026	Boost Price Target	$114.23	$134.00	Overweight
EXEL Exelixis	7/14/2026	Boost Price Target	$56.04	$49.00	Equal Weight
NUVL Nuvalent	6/9/2026	Reiterated Rating	$123.24	$124.00	Equal Weight
NUVL Nuvalent	6/9/2026	Downgrade	$123.35		Hold
JAZZ Jazz Pharmaceuticals	5/27/2026	Boost Price Target	$237.41	$253.00	Overweight
RLAY Relay Therapeutics	5/20/2026	Boost Price Target	$12.07	$27.00	Overweight
ARVN Arvinas	5/13/2026	Boost Price Target	$9.57	$20.00	Overweight
ANAB AnaptysBio	5/13/2026	Boost Price Target	$65.58	$75.00	Overweight
SRRK Scholar Rock	5/8/2026	Boost Price Target	$46.45	$55.00	Overweight
CLDX Celldex Therapeutics	5/8/2026	Boost Price Target	$33.05	$48.00	Overweight
JAZZ Jazz Pharmaceuticals	5/6/2026	Boost Price Target	$212.26	$234.00	Overweight
Major Buy Alert Issued for September 30th (Ad) Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now. See which stocks his AI research platform is flagging now
SNDX Syndax Pharmaceuticals	5/1/2026	Boost Price Target	$19.86	$37.00	Overweight
ORKA Oruka Therapeutics	4/27/2026	Boost Price Target	$82.33	$160.00	Overweight
TRAX First Tracks Biotherapeutics	4/22/2026	Initiated Coverage	$17.00	$40.00	Overweight
ANAB AnaptysBio	4/22/2026	Lower Price Target	$51.82	$63.00	Overweight
MGNX MacroGenics	4/20/2026	Boost Price Target	$3.46	$6.00	Overweight
JAZZ Jazz Pharmaceuticals	4/20/2026	Boost Price Target	$203.42	$225.00	Overweight
EXEL Exelixis	4/20/2026	Boost Price Target	$44.89	$45.00	Equal Weight
JANX Janux Therapeutics	4/20/2026	Downgrade	$15.82	$14.00	Underweight
CLDX Celldex Therapeutics	4/20/2026	Upgrade	$34.55	$45.00	Overweight
RLAY Relay Therapeutics	4/8/2026	Boost Price Target	$14.23	$21.00	Overweight
ORKA Oruka Therapeutics	4/7/2026	Boost Price Target	$58.94	$78.00	Overweight
TERN Terns Pharmaceuticals	3/30/2026	Reiterated Rating	$52.87	$53.00	Equal Weight
TERN Terns Pharmaceuticals	3/27/2026	Downgrade	$52.88		Hold
ABVX Abivax	3/24/2026	Boost Price Target	$115.07	$148.00	Overweight
PTGX Protagonist Therapeutics	3/19/2026	Boost Price Target	$102.06	$119.00	Overweight
CTMX CytomX Therapeutics	3/19/2026	Boost Price Target	$4.86	$16.00	Overweight
ORKA Oruka Therapeutics	3/13/2026	Boost Price Target	$39.79	$50.00	Overweight
BNTX BioNTech	3/11/2026	Lower Price Target	$91.57	$128.00	Outperform
MGNX MacroGenics	3/10/2026	Boost Price Target	$2.93	$4.00	Overweight
JAZZ Jazz Pharmaceuticals	3/9/2026	Reiterated Rating	$185.40	$224.00	Overweight
ANAB AnaptysBio	3/4/2026	Boost Price Target	$56.22	$79.00	Overweight
SRRK Scholar Rock	3/4/2026	Boost Price Target	$45.78	$70.00	Outperform
SRRK Scholar Rock	3/3/2026	Boost Price Target	$44.31	$53.00	Overweight
JAZZ Jazz Pharmaceuticals	2/27/2026	Initiated Coverage	$188.97	$224.00	Overweight
CCCC C4 Therapeutics	2/26/2026	Boost Price Target	$2.75	$7.00	Overweight
XNCR Xencor	2/26/2026	Boost Price Target	$13.37	$27.00	Overweight
PTGX Protagonist Therapeutics	2/26/2026	Boost Price Target	$86.70	$113.00	Overweight
IOVA Iovance Biotherapeutics	2/25/2026	Boost Price Target	$4.27	$11.00	Overweight
VIR Vir Biotechnology	2/24/2026	Boost Price Target	$9.50	$30.00	Overweight
INCY Incyte	2/18/2026	Boost Price Target	$101.16	$117.00	Overweight
VIR Vir Biotechnology	2/17/2026	Set Price Target	$7.47	$26.00
VIR Vir Biotechnology	2/4/2026	Reiterated Rating	$7.68	$24.00	Overweight
INCY Incyte	2/4/2026	Boost Price Target	$100.92	$116.00	Overweight
EXEL Exelixis	2/4/2026	Boost Price Target	$42.59	$44.00	Equal Weight
CTMX CytomX Therapeutics	2/4/2026	Boost Price Target	$6.07	$10.00	Overweight
RAPT Rapt Therapeutics	1/21/2026	Downgrade	$57.61	$58.00	Equal Weight
CRVS Corvus Pharmaceuticals	1/20/2026	Boost Price Target	$21.43	$28.00	Overweight
CTMX CytomX Therapeutics	1/20/2026	Boost Price Target	$5.39	$8.00	Overweight
ANAB AnaptysBio	1/20/2026	Boost Price Target	$45.68	$78.00	Overweight
XNCR Xencor	12/17/2025	Boost Price Target	$16.55	$26.00	Overweight
SRRK Scholar Rock	12/17/2025	Boost Price Target	$44.32	$52.00	Overweight
PTGX Protagonist Therapeutics	12/17/2025	Boost Price Target	$91.54	$108.00	Overweight
JANX Janux Therapeutics	12/17/2025	Lower Price Target	$14.65	$29.00	Overweight
IOVA Iovance Biotherapeutics	12/17/2025	Boost Price Target	$2.25	$10.00	Overweight
CCCC C4 Therapeutics	12/17/2025	Lower Price Target	$2.26	$5.00	Overweight
ARVN Arvinas	12/17/2025	Boost Price Target	$11.90	$18.00	Overweight
ANAB AnaptysBio	12/17/2025	Lower Price Target	$45.03	$55.00	Overweight
SMMT Summit Therapeutics	12/17/2025	Set Price Target	$17.23	$18.00
SMMT Summit Therapeutics	12/17/2025	Upgrade	$17.23	$18.00	Equal Weight
CLDX Celldex Therapeutics	12/17/2025	Boost Price Target	$26.61	$24.00	Underweight
Elon’s AI Phone is coming (Ad) Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. See the full evidence behind Elon Musk's rumored new device.
IOVA Iovance Biotherapeutics	12/17/2025	Boost Price Target	$2.82	$10.00	Overweight
TERN Terns Pharmaceuticals	12/9/2025	Boost Price Target	$40.23	$56.00	Overweight
KYMR Kymera Therapeutics	12/9/2025	Boost Price Target	$94.30	$119.00	Overweight
TERN Terns Pharmaceuticals	11/25/2025	Boost Price Target	$28.04	$36.00	Overweight
KURA Kura Oncology	11/24/2025	Reiterated Rating	$11.17	$28.00	Overweight
IOVA Iovance Biotherapeutics	11/24/2025	Boost Price Target	$2.24	$9.00	Overweight
SNDX Syndax Pharmaceuticals	11/24/2025	Boost Price Target	$18.44	$35.00	Overweight
NUVL Nuvalent	11/17/2025	Set Price Target	$108.00	$152.00
SRRK Scholar Rock	11/17/2025	Boost Price Target	$36.58	$45.00	Overweight
SRRK Scholar Rock	11/14/2025	Reiterated Rating	$37.47	$50.00	Outperform
TERN Terns Pharmaceuticals	11/11/2025	Boost Price Target	$19.12	$28.00	Overweight
ANAB AnaptysBio	11/11/2025	Lower Price Target	$33.98	$70.00	Overweight
CLDX Celldex Therapeutics	11/11/2025	Lower Price Target	$22.98	$21.00	Underweight
RAPT Rapt Therapeutics	11/7/2025	Lower Price Target	$28.60	$56.00	Overweight
PTGX Protagonist Therapeutics	11/7/2025	Boost Price Target	$78.49	$88.00	Overweight
JANX Janux Therapeutics	11/7/2025	Boost Price Target	$25.63	$48.00	Overweight
ARVN Arvinas	11/6/2025	Boost Price Target	$9.82	$16.00	Overweight
KYMR Kymera Therapeutics	11/5/2025	Boost Price Target	$59.91	$70.00	Overweight
EXEL Exelixis	11/5/2025	Boost Price Target	$37.90	$41.00	Equal Weight
TERN Terns Pharmaceuticals	11/4/2025	Boost Price Target	$14.03	$27.00	Overweight
XNCR Xencor	10/29/2025	Upgrade	$14.25	$23.00	Overweight
XNCR Xencor	10/29/2025	Upgrade	$14.25	$23.00	Overweight
TERN Terns Pharmaceuticals	10/22/2025	Lower Price Target	$7.61	$14.00	Overweight
SMMT Summit Therapeutics	10/21/2025	Boost Price Target	$20.03	$16.00	Underweight
CTMX CytomX Therapeutics	10/21/2025	Boost Price Target	$3.74	$6.00	Overweight
RAPT Rapt Therapeutics	10/21/2025	Boost Price Target	$33.67	$58.00	Overweight
TVRD Tvardi Therapeutics	10/13/2025	Set Price Target	$6.69	$5.00	Equal Weight
TVRD Tvardi Therapeutics	10/13/2025	Initiated Coverage	$41.60	$61.00	Overweight
RAPT Rapt Therapeutics	10/13/2025	Set Price Target	$26.79	$35.00	Overweight
ORKA Oruka Therapeutics	10/13/2025	Initiated Coverage	$24.49	$48.00	Overweight
MNPR Monopar Therapeutics	10/13/2025	Set Price Target	$87.82	$125.00	Overweight
CRVS Corvus Pharmaceuticals	10/13/2025	Initiated Coverage	$6.93	$16.00	Overweight
ANAB AnaptysBio	10/13/2025	Initiated Coverage	$31.37	$78.00	Overweight
ABVX Abivax	10/13/2025	Initiated Coverage	$93.77	$142.00	Overweight
CLDX Celldex Therapeutics	10/13/2025	Initiated Coverage	$26.77	$25.00	Underweight
ABVX Abivax	10/13/2025	Initiated Coverage	$95.63	$142.00	Overweight
ANAB AnaptysBio	10/13/2025	Initiated Coverage	$32.46	$78.00	Overweight
CRVS Corvus Pharmaceuticals	10/13/2025	Initiated Coverage	$7.11	$16.00	Overweight
MNPR Monopar Therapeutics	10/13/2025	Initiated Coverage	$102.05	$125.00	Overweight
ORKA Oruka Therapeutics	10/13/2025	Initiated Coverage	$25.50	$48.00	Overweight
RAPT Rapt Therapeutics	10/13/2025	Initiated Coverage	$26.35	$35.00	Overweight
TVRD Tvardi Therapeutics	10/13/2025	Initiated Coverage	$6.69	$61.00	Overweight
MRUS Merus	9/30/2025	Reiterated Rating	$93.67	$97.00	Equal Weight
MRUS Merus	9/30/2025	Downgrade	$94.15	$97.00	Equal Weight
SRRK Scholar Rock	9/24/2025	Lower Price Target	$33.75	$44.00	Overweight
CCCC C4 Therapeutics	9/22/2025	Boost Price Target	$3.16	$10.00	Overweight
XNCR Xencor	9/17/2025	Initiated Coverage	$8.62	$6.00	Underweight
MGNX MacroGenics	9/17/2025	Initiated Coverage	$1.47	$3.00	Overweight
EXEL Exelixis	9/17/2025	Initiated Coverage	$39.14	$40.00	Equal Weight
CTMX CytomX Therapeutics	9/17/2025	Initiated Coverage	$1.96	$3.50	Overweight
Major Buy Alert Issued for September 30th (Ad) Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now. See which stocks his AI research platform is flagging now
ARVN Arvinas	9/17/2025	Initiated Coverage	$7.64	$16.00	Overweight
TERN Terns Pharmaceuticals	9/17/2025	Initiated Coverage	$7.30	$15.00	Overweight
SMMT Summit Therapeutics	9/17/2025	Initiated Coverage	$18.12	$13.00	Underweight
SRRK Scholar Rock	9/17/2025	Initiated Coverage	$32.34	$45.00	Overweight
PTGX Protagonist Therapeutics	9/17/2025	Initiated Coverage	$58.59	$72.00	Overweight
MRUS Merus	9/17/2025	Initiated Coverage	$66.90	$112.00	Overweight
KYMR Kymera Therapeutics	9/17/2025	Initiated Coverage	$48.78	$60.00	Overweight
JANX Janux Therapeutics	9/17/2025	Initiated Coverage	$23.41	$47.00	Overweight
CCCC C4 Therapeutics	9/17/2025	Initiated Coverage	$3.41	$8.00	Overweight
ARVN Arvinas	9/16/2025	Upgrade	$7.61		Strong-Buy
CCCC C4 Therapeutics	9/16/2025	Initiated Coverage	$3.38	$8.00	Overweight
CTMX CytomX Therapeutics	9/16/2025	Upgrade	$1.93		Strong-Buy
EXEL Exelixis	9/16/2025	Upgrade	$40.44		Hold
JANX Janux Therapeutics	9/16/2025	Initiated Coverage	$23.46	$47.00	Overweight
KYMR Kymera Therapeutics	9/16/2025	Initiated Coverage	$48.12	$60.00	Overweight
MGNX MacroGenics	9/16/2025	Upgrade	$1.53		Strong-Buy
MRUS Merus	9/16/2025	Initiated Coverage	$68.18	$112.00	Overweight
PTGX Protagonist Therapeutics	9/16/2025	Initiated Coverage	$59.22	$72.00	Overweight
SMMT Summit Therapeutics	9/16/2025	Initiated Coverage	$18.09	$13.00	Underweight
SRRK Scholar Rock	9/16/2025	Initiated Coverage	$31.95	$45.00	Overweight
TERN Terns Pharmaceuticals	9/16/2025	Initiated Coverage	$7.40	$15.00	Overweight
XNCR Xencor	9/16/2025	Upgrade	$9.25		Strong Sell
IVA Inventiva	9/2/2025	Boost Price Target	$6.19	$13.00	Buy
SRRK Scholar Rock	8/7/2025	Lower Price Target	$34.62	$45.00	Outperform
TERN Terns Pharmaceuticals	5/13/2025	Lower Price Target	$2.93	$15.00	Outperform
IVA Inventiva	4/4/2025	Lower Price Target	$3.26	$9.00	Buy
ARVN Arvinas	3/12/2025	Set Price Target	$8.51	$20.00	Outperform
BNTX BioNTech	3/11/2025	Boost Price Target	$105.35	$143.00	Outperform
ARVN Arvinas	2/12/2025	Reiterated Rating	$18.88	$82.00	Outperform

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Etzer Darout Analyst Performance

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Etzer Darout Analyst Performance

Analyst Rankings, Coverage, and Performance Statistics

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

Etzer Darout's Ratings History at BMO Capital Markets

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools